• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Show Search
Home
EN / FR
  • LinkedIn
  • Twitter
Celyad Oncology

Celyad Oncology

  • About Us
    • Overview
    • Management Team
    • Board Of Directors
    • Scientific Advisory Board
    • Partners
  • Science
    • Overview
    • Approach
    • Technology
      • TIM
      • shRNA
    • Manufacturing
    • Scientific Publications
  • Pipeline
  • Newsroom
    • Press Releases
    • Events
    • Media Center
  • Investors
    • Overview
    • Analyst Coverage
    • Corporate Governance
    • Regulated Information
    • Shareholders Information
    • Shareholders Meeting
  • Contact Us
    • Careers

Cardio3 BioSciences Appoints Hanspeter Spek, Senior Pharmaceutical Executive to its Board of Directors

March 31, 2014 By Celyad

Mont-Saint-Guibert, Belgium, –Cardio3 BioSciences (C3BS) (NYSE Euronext Brussels and Paris: CARD), a leader in the discovery and development of regenerative, protective and reconstructive therapies for the treatment of cardiac diseases, today announces it intends to appoint Hanspeter Spek as a Non- Executive Director. The appointment is expected to be formalized at C3BS’ next general assembly on May 5th 2014.

Hanspeter started his career at Pfizer where, over more than ten years and after a thorough comprehensive training in commercial general management, he held positions of increasing responsibility. He then joined Sanofi as Marketing Director and rose through the organization to become the Executive Vice President International in 2000. When Sanofi and Aventis merged in 2004, he took on the responsibility of Executive Vice President Operations. In 2009, he was nominated President Global Operations. He retired from Sanofi in mid-2013. He has since joined Advent as a Senior Advisor for Healthcare. He continues to serve on the Board of Sanofi, Germany, as Chairman.

Dr Christian Homsy, CEO of Cardio3 BioSciences comments: “We are extremely proud that an executive of the caliber of Hanspeter has decided to join the Board of C3BS, reflecting our leadership in our field. His extensive experience in building partnerships and leading operations, marketing and sales will be invaluable in best preparing our company to commercialize C-Cure®. As a member of the Executive Committee at Sanofi, Hanspeter has been a key participant in numerous partnerships, acquisitions and licensing deals, and, as such, he will further enhance our capability to pursue business development opportunities and allow us to benefit from his perspective as a large healthcare industry executive.”

Commenting on his new role, Hanspeter Spek said: “I am honored to have the opportunity to contribute to the future development of C3BS. With the CHART-1 Phase III program running in Europe and approval to commence CHART-2 from the US FDA, the Company is positioned at the forefront of regenerative medicine. Heart disease remains an area of substantial unmet medical need and I look forward to bringing my experience of development, launch preparation and worldwide commercialization to the Board and to working with the team to deliver on C-Cure’s potential.” 

Download press release(s)
Communiqué de presse
Press Release

Filed Under: Corporate, Non-regulated

Footer

  • About
  • Science
  • Pipeline
  • Newsroom
  • Investors
  • Contact Us
  • LinkedIn
  • Twitter

Copyright © 2020 All Rights Reserved.
Cookie Policy | Privacy Policy | Terms of Use

Our website uses cookies including analytics cookies to help improve it by collecting statistics on how visitors use our website. By clicking on "I accept", you allow us to place these analytics cookies. We also use cookies that are necessary for the good functioning of our website. You can find out more information about the cookies we use by visiting our Cookie Policy. I acceptI refuseCookie Policy